Abstract Although poly (ADP-ribose) polymerase-1 (PARP1) inhibition is a recent promising therapy in breast cancer, PARP1 expression in this disease is not known. Using DNA microarray and array-based comparative genomic hybridization (arrayCGH), we examined PARP1 mRNA expression and copy number alterations in 326 invasive breast cancer samples and normal breast (NB) samples. A metaanalysis was performed on a large public retrospective gene expression data set (n = 2,485) to analyze correlation between PARP1 mRNA expression and molecular subtypes and clinico-pathological parameters. PARP1 was overexpressed in 58% of cancers, and its expression was heterogeneous between tumors. ArrayCGH data revealed an association between mRNA overexpression and gain/amplification at the PARP1 locus (P \ 1.0E-8). Meta-analysis showed that PARP1 expression was higher in basal breast cancers (P \ 1.0E-72), but overexpression was also found in other subtypes. PARP1 expression correlated with high grade, medullary histological type, tumor size, and worse metastasisfree survival (MFS; HR = 1.12 [1.04-1.22], P = 0.004) and overall survival (OS; HR = 1.16 [1.04-1.29], P = 0.006). In multivariate analysis, PARP1 expression had an independent prognostic value for MFS, which was restricted to patients untreated with any adjuvant chemotherapy. These data demonstrate overexpression of PARP1 in a large number of breast cancers and support the development of PARP inhibitors in basal subtype, but also potentially in other breast cancer subtypes.
Introduction
Poly(ADP-ribose) polymerase-1 (PARP1), the most abundant member of the PARP superfamily, is a nuclear chromatin-associated protein involved in a wide range of biologic processes including cell proliferation, apoptosis, malignant transformation, transcriptional regulation, and DNA repair. PARP1 is essential to the base excision repair of DNA single-strand breaks (SSBs) [1] . In response to DNA damage, PARP1 senses and binds to DNA nicks and breaks, resulting in activation of catalytic activity, causing poly(ADP)ribosylation of PARP1 itself, as well as other acceptor proteins, such as histones and topoisomerases. This modification potentially stimulates the recruitment and activity of other components of DNA repair pathways [1] . In its absence, DNA SSBs accumulate and degenerate to DNA double-strand breaks (DSBs), which are not appropriately repaired if the BRCA pathway is deficient or dysfunctional. This seems to explain the exquisite sensitivity to PARP inhibitors of tumors with BRCA inactivation, a concept called ''synthetic lethality'' [2, 3] . Recent clinical evidence confirmed that PARP inhibition is a promising therapeutic strategy either as single-agent in BRCA1 or BRCA2-mutated breast cancers [4] , or in combination with cytotoxic chemotherapy in triple-negative (TN) breast cancers, a subgroup that shares many features with BRCA1-mutated tumors [5] . Several PARP inhibitors are currently in clinical development. However, until now, PARP1 mRNA expression has not been described in breast cancer. A few and relatively small (less than 95 samples) studies have been reported in melanoma [6, 7] , ovarian cancer [8] , and colon cancer [9] , and showed frequent PARP1 overexpression, associated with poor-prognosis histo-clinical features.
In this study, we explored our gene expression database of 326 breast cancer samples profiled using oligonucleotide microarrays. Data were then combined with 12 publicly available expression data sets, resulting in a total of 2,485 invasive breast cancers informative for meta-analysis. Our primary objective was to describe the molecular epidemiology of this novel therapeutic target in a large population of early breast cancer patients. Secondary objectives included correlation between PARP1 expression and other clinical, pathological, and molecular features, including survival.
Patients and methods

Gene expression data of breast cancer
To determine PARP1 mRNA expression in breast cancer, we analyzed gene expression data of 326 breast tumor samples that we had profiled using oligonucleotide microarrays. Tumor tissues had been collected from 326 patients with invasive adenocarcinoma, who underwent initial surgery at the Institut Paoli-Calmettes (Marseilles, France) between 1987 and 2007. Each patient gave written informed consent, and the study was approved by our institutional review board. Samples were macrodissected and frozen in liquid nitrogen within 30 min of removal. All the specimens contained [60% of tumor cells (as assessed before RNA extraction using frozen sections adjacent to the profiled samples). After surgery, patients were treated using a multimodal approach according to standard guidelines. DNA and RNA were extracted from frozen samples using guanidium isothiocynanate and cesium chloride gradient as described previously [10] . RNA integrity was controlled on Agilent Bioanalyzer (Agilent Technologies). We had also profiled 11 normal breast (NB) tissue samples pooled in four RNA samples. Expression profiles had been established for these 326 cancers and four NB pools with Affymetrix U133 Plus 2.0 human oligonucleotide microarrays as previously described [11] . Scanning was done with Affymetrix GeneArray scanner and quantification with Affymetrix GeneChip Operating Software. Data were analyzed by the Robust Multichip Average method [12] in R using Bioconductor and associated packages. PARP1 expression was measured by analyzing the sole probe set present on our Affymetrix microarrays, ID 208644_at. Before analysis, gene expression levels for each tumor sample were centered by the average expression levels of the four NB samples. All data were then log2 transformed for display and analysis.
To examine the correlation between PARP1 mRNA expression and histo-clinical features of tumors in a large series of samples, we analyzed 12 publicly available data sets collected from the National Center for Biotechnology Information (NCBI)/GenBank GEO database (series entry  GSE2034, GSE2990, GSE4922, GSE1456, GSE7390, GSE  2741, GSE1992, GSE2740, GSE2607, GSE6130, GSE3165,  GSE6128, GSE10886) or at the following web addresses http://bioinformatics.mdanderson.org/pubdata.html;http:// microarray-pubs.stanford.edu/wound_NKI/; http://www. rii.com/publications/2002/vantveer.html. To be comparable across data sets and to exclude bias from population heterogeneity, PARP1 expression levels were standardized within data sets using the luminal A population as reference. Combined with our IPC series, this resulted in a total of 2,485 invasive breast cancers with PARP1 expression and histo-clinical data available for meta-analysis ( Table 1) .
The molecular subtypes related to the Stanford intrinsic breast cancer classification were determined using single sample predictor (SSP) classifier based on a list of 306 intrinsic genes [13] . In brief, after having identified the genes common between the intrinsic gene set and each expression data set, we then used distance weighted discrimination (DWD) [14] to normalize each data set to be comparable to the 315 samples of the Hu's combined test sample set. Next, we defined the expression centroid of each subtype for the common probe sets in this combined test sample set [13] . Finally, we measured the correlation of each sample with each centroid. The sample was attributed the subtype corresponding to the most correlated centroid.
Array-comparative genomic hybridization (aCGH) data of breast cancer Our analysis included data of genomic imbalances of 260 out of the 326 breast tumors. Data had been generated by aCGH using 244K CGH Microarrays (Hu-244A, Agilent Technologies) as per a described protocol [10] . A pool of 13 normal male DNA had been used as reference. Scanning was done with Agilent Autofocus Dynamic Scanner (G2565BA, Agilent Technologies). Data analysis was done as described [10] . Extraction of data (log2 ratio) was done from CGH Analytics, whereas normalized and filtered log2 ratio was obtained from ''Feature Extraction'' software (Agilent Technologies). The PARP1 locus at 1q41 was analyzed, and copy number changes were characterized as reported previously [10] . Eight probes matched the PARP1 gene on our Agilent chips. A tumor was considered as harboring a gain for PARP1 if at least five (out of eight) consecutive probes displayed a log2 ratio of tumor/normal [|0.5|.
Statistical analyses
Study is retrospective and multicentric based on a large public data set. Comparisons of mean PARP1 expression level according to classical histo-clinical factors were done using Student t-test (two variables) or one-way analysis of variance (ANOVA; more than two variables). Metastasisfree survival (MFS) was calculated from the date of diagnosis until date of distant relapse, and follow-up was measured from the date of diagnosis to the date of last news for patients without relapse. Overall survival (OS) was calculated from the date of diagnosis until date of death, and follow-up was measured from the date of diagnosis to [15] .
Results
PARP1 mRNA expression and DNA copy number: IPC series
We analyzed expression data generated using Affymetrix microarrays from 330 samples including 326 pre-treatment primary breast cancers and four NB samples collected at our institution. First, we observed that PARP1 mRNA expression was highly heterogeneous, with expression level varying across a large dynamic range and encompassing almost four base 2 logs. To address the impact of potential intra-tumor heterogeneity in this pattern, we took advantage of recently published microarray data generated from a series of 18 breast cancer samples [16] . In this study, gene expression profiles obtained from two to three biopsy replicates of the same tumor sample were available for comparison; we observed an intra-patient PARP1 mRNA expression variance significantly lower than interpatient variance (P = 9.19E-29, ANOVA), suggesting that intra-tumor heterogeneity has a minor influence on the heterogeneous expression of PARP1 that we have observed. Whole-genome hierarchical clustering showed that PARP1 was located within a proliferation gene cluster, including, for example, MKI67 and PCNA, along with other genes involved in DNA damage repair such as RAD51 and ERCC4. Of note, PARP1 expression did not correlate with BRCA1 and BRCA2 expression (data not shown).
Compared to NB, PARP1 was overexpressed (C twofold increase) in 58% of cancer samples (Fig. 1a) . aCGH data, simultaneously available for 260 of the 326 samples, allowed us to analyze the PARP1 locus at 1q41. Amplification of the 1q41-q44 region is a frequent genetic alteration in breast cancer [17] [18] [19] . A significant genomic gain (log2 ratio [|0.5|) or amplification (log2 ratio [|1|) was observed in 91 out of 260 (35%) samples (the mean percent of probes displaying this copy number alteration was 99.2% [95 CI, 97.8-100] within the 91 altered tumors). Moreover, a significant association between PARP1 mRNA expression and gene copies was observed: the mean expression level of PARP1 mRNA was more than twice higher in tumors with PARP1 gain or amplification compared to tumors displaying a normal gene copy number (P \ 1.E-8, t-test; Fig. 1b) . However, gain/amplification was not the sole mechanism of overexpression, which was also found in tumors without any gene copy number gain.
PARP1 mRNA expression and histo-clinical correlations: meta-analysis Meta-analysis examined correlations between PARP1 mRNA expression and histo-clinical features of tumors in a data set of 2,485 invasive breast cancer samples, including our series and 12 public microarray data sets. As shown in Table 2 , PARP1 expression was significantly (t-test) associated with IHC negativity for ER, PR, and ERBB2, with high grade, histological type (being the highest in medullary cancers and the lowest in lobular tumors), high pathological tumor size, with a trend for axillary lymph node involvement (P = 0.067), but not with age. For 430 cases with available IHC information, PARP1 expression was higher in TN samples (negative for ER, PR, and ERBB2), compared to ERBB2? (positive for ERBB2, whatever the ER and PR status) and ERBB2-/HR? (positive for ER and/or PR, negative for ERBB2) samples (P = 0.05, oneway ANOVA, data not shown).
We looked for PARP1 expression in the transcriptional molecular subtypes defined by the intrinsic gene set [13] . PARP1 was overexpressed in basal samples compared to other subtypes (Fig. 2) . Interestingly, PARP1 expression was much more tightly associated with the basal subtype than with the TN subgroup. Indeed, among the 430 abovedescribed cases with available IHC classification, the correlation of PARP1 mRNA with the molecular subtypes (basal, ERBB2, and others) was high (P = 4.6E-6, oneway ANOVA) and greatly superior to that observed with the IHC classification (data not shown). Examining the sole IPC data set (where simultaneous mRNA and genomic data were available), it was possible to address within each molecular subtype the above-described association between PARP1 expression and gene copy gain. The association was significant (t-test) in basal (P = 5.06E-4), ERBB2 (P = 7.2E-3), and luminal B (P = 6.28E-3) samples, but not in luminal A and normal samples. PARP1 was overexpressed in 84, 100, and 79% of PARP1-amplified/ gained basal, ERBB2 and luminal B samples, respectively, versus 61 and 50% of luminal A and normal samples, respectively.
Finally, we examined the prognostic impact of PARP1 expression, along with other known clinical or pathological factors. We first examined MFS. In this series, follow-up was available for 1,637 patients: 494 women developed metastatic relapse with a median time to relapse of 32 months, and 1,143 remained relapse-free with a median follow-up of 96 months. In univariate analysis, PARP1 expression (together with pN, pT, grade, and ER, PR, and ERBB2 IHC status) was associated with a worse MFS (HR = 1.12 [1.04-1.22]; P = 0.004; Fig. 3a) . However, this was not maintained in multivariate analysis (data not shown). Since potential prognostic factors for MFS may interact with and thus be confounded by systemic adjuvant therapies, we re-analyzed data according to the treatment received, adjuvant chemotherapy and/or hormonal therapy, no patient being exposed to adjuvant trastuzumab. There were 261 patients who had not received any adjuvant systemic therapy (subgroup CT0HT0). Among them, 91 developed metastatic relapse with a median time to relapse of 27 months, and 170 remained relapse-free with a median follow-up of 99 months. There were 602 patients who had not received any adjuvant chemotherapy, with or without hormonal therapy (subgroup CT0HT?/-), including 210 who experienced metastatic relapse with a median time of 28 months, and 392 who did not relapse with a median follow-up of 100 months. As shown in Table 3 (Fig. 3b) .
Discussion
To date PARP1 mRNA expression and DNA copy number alterations have not been described in breast cancer. In this large series, we show that PARP1 expression is heterogeneous, with overexpression found in a significant number of breast cancers, in part due to genomic gain/amplification. This is particularly true in TN and even more in basal samples, and to a lesser degree in ERBB2? and luminal samples. However, the role of such an overexpression in tumor initiation or progression, if any, remains to be elucidated. In addition, and for the first time to our knowledge, we have shown a significant and independent association between PARP1 expression and MFS in breast cancer. Importantly, this association was restricted to patients not treated with any adjuvant chemotherapy. Exploiting DNA repair alterations using PARP inhibition [4, 5] was recently shown as a promising approach in BRCA-mutated or TN breast cancers, which are classically associated with the basal subtype [20] . Thus, in a phase I dose-escalation study, Fong and colleagues selected a population enriched in BRCA-associated cancers [4] . In the non-mutated population, there was no objective response. In the group of 19 patients with a documented BRCA mutation, including breast, ovarian, and prostate malignancies, there was a 47% response rate and a 63% clinical benefit rate. In TN breast cancer, a randomized phase II study compared addition of a PARP1 inhibitor, BSI-201, to chemotherapy with gemcitabine and carboplatin versus chemotherapy alone [5] . Preliminary data demonstrated that the addition of BSI-201 was associated with highly significant improvements in response (from 16 to 48%), in progression-free survival (median from 3.3 to 6.9 months), as well as OS. A randomized phase III study is currently underway to confirm these results with gemcitabine, carboplatin, and BSI-201. Moreover, cisplatin-based neoadjuvant treatment [21] provided dramatic pathological response rate (nearly 75%) in a small-sized population of tumors occurring in BRCA-mutated patients. In addition, cisplatin as singleagent induced a promising response rate of 22% in TN breast cancer, which was correlated with low BRCA expression [22] . These convergent clinical data suggest that tumors with deficient DNA-repair phenotypes, thought to be enriched in BRCA-mutated and TN subtypes, could be very sensitive to PARP inhibitors and DNA-damaging agents, alone or in combination. However, reliable and robust biomarkers that allow the accurate identification of alterations in functional DNA repair pathways (the so-called ''BRCAness'' phenotype, with the highest probability to benefit from these therapies) are still lacking. It still remains to be demonstrated whether the major increase in PARP1 expression observed in our study in some breast cancers might be such a marker. Speculatively, it could reflect a regulatory response to genetic instability, aiming to compensate for an abnormal rate of DNA damages, PARP1 mRNA level (log 2 ) Fig. 2 mRNA expression of PARP1 according to breast cancer molecular subtypes. PARP1 expression across 2,485 breast cancer (BC) samples with publicly available data was examined according to molecular subtypes as defined in [13] . Box plots of PARP1 expression in BC are shown according to basal, ERBB2, luminal A and B, and normallike subtypes. Differences in PARP1 expression levels between the subtypes were tested for significance using one-way ANOVA. For each box plot, median and ranges are indicated
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Low PARP1 explaining why this event is more pregnant in the most instable subtypes, such as TN and basal. In this regard, our observation that the prognostic value of PARP1 expression was lost in patients receiving adjuvant chemotherapy could suggest that overexpression of PARP1 may be associated with tumor sensitivity to cytotoxic treatment, essentially cyclophosphamide and/or anthracycline-based in our retrospective series. Such a hypothesis is consistent with the recently reported positive correlation between PARP1 protein expression and response to neoadjuvant chemotherapy [23, 24] . In this study, 646 breast cancer samples from the GeparTrio neoadjuvant phase III trial were centrally stained by IHC for PARP protein. Similar to what we observed at the mRNA level, PARP protein was found in all molecular subtypes, more frequently in ERBB2-positive and TN tumors, and correlated with the most known prognostic factors, including poor differentiation, non-lobular histological type, and negative hormonal receptivity. Notably, PARP expression independently predicted for the pathological complete response (pCR) to neoadjuvant taxane-anthracycline-based chemotherapy: patients with high expression showed a pCR rate of 25.7% compared to 18.8 and 6.1% in patients with medium or low expression (P \ 0.001). Interestingly, it is worth emphasizing that the deficient DNA-repair phenotype may be observed beyond these subtypes. For example, recent data have suggested that PTEN deficiency may associate with reduction in RAD51 expression and perturbation of homologous recombination in BRCA-intact human cancer cells, leading to high sensitivity to PARP inhibition [25] . Moreover, a similar deficiency in DSBs repair may be functionally induced in various non-genetic conditions, including hypoxia or even PARP inhibition itself, both setting being associated with a repression in BRCA1 and RAD51 transcription and therefore an increased efficiency of anti-PARP treatment [26] . Altogether, these data support the hypothesis that PARP inhibition may have broader applications in breast cancer treatment than anticipated based on initial preclinical and clinical results.
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In conclusion, we report the first large-scale integrated analysis of PARP1 expression and genomic status in breast cancer. Whether PARP1 overexpression may identify breast cancers with higher probability of response to PARP inhibitors or DNA-damaging agents needs to be determined. However, if this hypothesis were confirmed, our data should not only strengthen the interest for these compounds in basal breast cancers, but also suggest promising applications in a larger fraction of patients, beyond the basal subtype. 
